Pelthos Therapeutics Inc. (PTHS)
(Real Time Quote from BATS)
$20.10 USD
-0.90 (-4.29%)
Updated Aug 6, 2025 02:24 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PTHS 20.10 -0.90(-4.29%)
Will PTHS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTHS based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for PTHS
Pelthos Therapeutics (PTHS) Sees Price Target Boost Post-Merger | PTHS Stock News
Pelthos Therapeutics target adjusted at Alliance after merger, reverse split
12 Health Care Stocks Moving In Friday's Intraday Session
12 Health Care Stocks Moving In Thursday's Intraday Session
Pelthos Therapeutics Launches First At-Home Prescription Gel For Highly Contagious Skin Disease